Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

1.9K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Redo-Transcatheter Aortic Valve Implantation (Redo-TAVI)-Pilot Study from Multicentre Nationwide Registry.

Journal of clinical medicine·2025
Same author

Treatment of Severe Tricuspid Regurgitation with the TricValve System Implantation-Preliminary Results of a Prospective Registry.

Journal of clinical medicine·2025
Same author

Vessel-Specific Myocardial Mass in Patients With Stable Coronary Artery Disease.

Journal of the American Heart Association·2025
Same author

Ischemic Complications in a Patient With Spontaneous Echo Contrast Undergoing Percutaneous Left Atrial Appendage Closure.

JACC. Case reports·2025
Same author

Cost-utility analysis of the use of a wearable cardioverter defibrillator (LifeVest®) versus standard of care in the prevention of sudden cardiac death in patients after myocardial infarction.

Kardiologia polska·2025
Same author

Cardiology in Poland: A report for the year 2024 - part 2: Electrophysiology and device therapy.

Kardiologia polska·2025

Related Experiment Video

Updated: May 2, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.6K

Renal denervation - current evidence and perspectives.

Ewa Warchoł-Celińska1, Aleksander Prejbisz1, Elżbieta Florczak1

  • 1Institute of Cardiology, Warsaw, Poland.

Postepy W Kardiologii Interwencyjnej = Advances in Interventional Cardiology
|February 27, 2014
PubMed
Summary
This summary is machine-generated.

Catheter-based renal denervation (RDN) effectively lowers blood pressure in resistant hypertension patients for up to 36 months. Further trials are needed to confirm long-term safety and efficacy against medications.

Keywords:
hypertensionrenal denervationresistant hypertension

More Related Videos

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
04:37

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension

Published on: June 6, 2025

847
Quantifying Acute Changes in Renal Sympathetic Nerve Activity in Response to Central Nervous System Manipulations in Anesthetized Rats
06:30

Quantifying Acute Changes in Renal Sympathetic Nerve Activity in Response to Central Nervous System Manipulations in Anesthetized Rats

Published on: September 11, 2018

7.4K

Related Experiment Videos

Last Updated: May 2, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.6K
Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
04:37

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension

Published on: June 6, 2025

847
Quantifying Acute Changes in Renal Sympathetic Nerve Activity in Response to Central Nervous System Manipulations in Anesthetized Rats
06:30

Quantifying Acute Changes in Renal Sympathetic Nerve Activity in Response to Central Nervous System Manipulations in Anesthetized Rats

Published on: September 11, 2018

7.4K

Area of Science:

  • Cardiology
  • Nephrology
  • Interventional Cardiology

Background:

  • Resistant hypertension poses a significant clinical challenge, often requiring advanced therapeutic strategies.
  • Catheter-based renal denervation (RDN) has emerged as a promising interventional approach for managing difficult-to-treat hypertension.
  • Existing clinical data suggest RDN offers a sustained blood pressure-lowering effect, potentially lasting up to 36 months.

Purpose of the Study:

  • To evaluate the long-term safety and efficacy of catheter-based renal denervation (RDN) compared to optimal pharmacological treatment.
  • To identify patient subgroups who are most likely to benefit from RDN and characterize non-responders.
  • To explore the potential of RDN for new indications beyond resistant hypertension, targeting conditions with sympathetic nervous system overactivation.

Main Methods:

  • Review of clinical trial data assessing the outcomes of catheter-based renal denervation.
  • Analysis of blood pressure reduction and control in patients with resistant hypertension.
  • Exploration of potential benefits in co-morbidities like metabolic syndrome, sleep apnea, CKD, heart failure, and arrhythmias.

Main Results:

  • Clinical trials confirm that RDN significantly reduces blood pressure and improves control in resistant hypertension.
  • The blood pressure-lowering effect of RDN has been observed to persist for up to 36 months in follow-up studies.
  • Preliminary evidence suggests RDN may benefit conditions associated with sympathetic overactivity, though larger trials are required.

Conclusions:

  • Catheter-based RDN is a promising therapeutic option for resistant hypertension with potentially durable effects.
  • Further large-scale clinical trials are essential to establish long-term safety and compare RDN's efficacy against best medical therapy.
  • Identifying responders and expanding RDN indications to other sympathetic-driven diseases requires further investigation.